- About About
-
Medical
Medical
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor Which conditions qualify? The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
-
Advocacy
Advocacy
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
- News News
-
Policy
Policy
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Reports 2020 State of the States Medical Cannabis Access for Pain Treatment Medical Cannabis in America Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit
- Join Join
-
-
Israel & Canada Move Ahead, while US Lags Behind in Medical Marijuana Research
Earlier this month, there were two exciting developments for medical cannabis internationally. In Israel, a Tel Aviv medical clinic began dispensing medical cannabis to patients in need, while in Canada, a federal court ruling ended the monopoly a federal contractor has on supplying cannabis to patients, opening up possibilities for dispensaries and collective production of medicine.
Our international counterparts may be surging ahead in their paths to provide safe access for patients who benefit from medical cannabis, but here in the US, it's sometimes hard to move to the conversation about access when our government barely budges on research issues. The DEA continues to uphold a monopoly on the production of cannabis for research, even though it's own administrative law judge recommended ending this monopoly by granting a license to Professor Lyle Craker to grow research material.
While whole plant medical cannabis is being stonewalled though, GW Pharmaceuticals is moving rapidly through Phase III trials in the US for Sativex, a cannabis-based tincture. GW's chairman, Dr. Geoffrey Guy, had this to say about the progress of Sativex:
"2008 promises to be an equally eventful year for GW, with the results of a number of key Sativex Phase III trials in Europe and the US due to be reported. The momentum behind Sativex and the wider field of cannabinoid medicines, as highlighted today by the promising results of our THCV metabolic research programme, continues to grow..."It's good to know that GW recognizes the potential for a wider field of cannabis medicine, but until the monopoly on production of cannabis for research is ended, it will be difficult for researchers to push this field forward in the United States. Until then, at least patients in Israel are happy: "One cancer patient said the ministry's decision to offer the drug through the clinic was "a blessing," saying it prevents suffering patients from being driven to buy the drug illegally."
Share
Focus on Your State!
